ENTX — Entera Bio Ltd
NASDAQ · Healthcare · Biotechnology
$2.90
+$0.00 (+0.00%)
Entera Bio Ltd (ENTX) is a biotechnology company listed on NASDAQ. It is led by Miranda J. Toledano M.B.A., based in Kiryat Hadassah Minrav Building, Jerusalem, Israel, 9112002, with about 20 employees. Entera Bio Ltd., a clinical stage company, engages in the development of oral peptides and protein replacement therapies in Israel and internationally. It develops EB613, an oral teriparatide, which completed the Phase II clinical trial for the treatment of osteoporosis and Phase I clinical trial for the treatment of stress fractures. The company is also involved in the development of EB612, a tablet peptide replacement therapy, which is in Phase I clinical trial for the treatment of hypoparathyroidism; EB618, a GLP-1/glucagon dual agonist peptide, which is in Phase I clinical trial for the treatment of obesity, metabolic, and fibrotic disorders; and GLP-2 which is in Phase I clinical trial for the treatment of short bowel syndrome and disorders related to mucosal inflammation and nutrient malabsorption. It has a collaboration agreement with OPKO Biologics, Inc for the preclinical and clinical development of LA-PTH and oral dual agonist GLP-1/glucagon peptide. The company was incorporated in 2009 and is based in Jerusalem, Israel.
Latest reported ENTX revenue for 2025-09-30 was $0. Net income was -$3.2M. ENTX currently screens at market cap $58.2M.
Use this ENTX page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the ENTX quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the ENTX SEC filings page. Lician reads the product cache first so this HTML stays unique to Entera Bio Ltd even when a live quote feed is slow.
About Entera Bio Ltd
Entera Bio Ltd., a clinical stage company, engages in the development of oral peptides and protein replacement therapies in Israel and internationally. It develops EB613, an oral teriparatide, which completed the Phase II clinical trial for the treatment of osteoporosis and Phase I clinical trial for the treatment of stress fractures. The company is also involved in the development of EB612, a tablet peptide replacement therapy, which is in Phase I clinical trial for the treatment of hypoparathyroidism; EB618, a GLP-1/glucagon dual agonist peptide, which is in Phase I clinical trial for the treatment of obesity, metabolic, and fibrotic disorders; and GLP-2 which is in Phase I clinical trial for the treatment of short bowel syndrome and disorders related to mucosal inflammation and nutrient malabsorption. It has a collaboration agreement with OPKO Biologics, Inc for the preclinical and clinical development of LA-PTH and oral dual agonist GLP-1/glucagon peptide. The company was incorporated in 2009 and is based in Jerusalem, Israel.
ENTX Key Statistics
Market Cap
$58.16M
Volume
116,906
Previous Close
$3.42
Day Range
$3.41 – $3.56
EPS
$0.25
Revenue
$181.00K
Net Income
-$9.54M
Gross Profit
$0.00
Free Cash Flow
$0.00
Profit Margin
-5271.3%
Employees
20
ENTX Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $181.00K | $0.00 | $134.00K | $571.00K |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$9.54M | -$8.89M | -$13.07M | -$12.19M |
| EPS (Diluted) | $0.25 | $0.31 | $0.45 | $0.47 |
Total Assets
$9.39M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$8.66M
Operating Cash Flow
-$6.82M
Free Cash Flow
$0.00
Entera Bio Ltd Company Information
- CEO & Director
- Miranda J. Toledano M.B.A.
- Headquarters
- Kiryat Hadassah Minrav Building, Jerusalem, Israel, 9112002
- Website
- enterabio.com
- Phone
- 972 2 532 7151
- IPO / Founded
- 2018-06-28
- Sector
- Healthcare
- Industry
- Biotechnology